58
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials

, , , , , & show all
Pages 657-673 | Published online: 24 Jun 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Sowmya P Lakshmi, Aravind T Reddy & Raju C Reddy. (2017) Emerging pharmaceutical therapies for COPD. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 2141-2156.
Read now

Articles from other publishers (7)

Sadia Janjua, Rebecca Fortescue & Phillippa Poole. (2020) Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2020:5.
Crossref
Lu-Fei Shen, Xiao-Dong Lv, Wen-Yu Chen, Qi Yang, Zhi-Xian Fang & Wei-Fen Lu. (2018) Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis. Irish Journal of Medical Science (1971 -) 187:3, pages 731-738.
Crossref
Barbara J. Messinger-Rapport, Milta O. Little, John E. Morley & Julie K. Gammack. (2017) Clinical Update on Nursing Home Medicine: 2017. Journal of the American Medical Directors Association 18:11, pages 928-940.
Crossref
Jimmy Chong, Bonnie Leung & Phillippa Poole. (2017) Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews.
Crossref
Štefan Laššán, Marta Hájková & Monika Laššánová. (2017) Anti-inflammatory treatment of stable COPD - current trends and recommendations for clinical practiceExperts statement. Klinická farmakologie a farmacie 31:1, pages 22-30.
Crossref
Karly P. Garnock-Jones. (2015) Roflumilast: A Review in COPD. Drugs 75:14, pages 1645-1656.
Crossref
Ana R. Nunes, Andrew P. Holmes, Sílvia V. Conde, Estelle B. Gauda & Emília C. Monteiro. (2014) Revisiting cAMP signaling in the carotid body. Frontiers in Physiology 5.
Crossref